Cantor Fitzgerald Says Buy Avita Medical Ltd. (RCEL) on Weakness Following Q1 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AVITA Medical Reports First Quarter 2025 Financial Results
May 8, 2025 4:03 PM EDTVALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights and Recent Developments
Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx, an... More